

Naval G Daver

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1006749/publications.pdf>

Version: 2024-02-01

274
papers

15,605
citations

22153

59
h-index

24982

109
g-index

279
all docs

279
docs citations

279
times ranked

12489
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric antigen receptor T-cell therapy "assessment and management of toxicities. Nature Reviews Clinical Oncology, 2018, 15, 47-62.	27.6	1,659
2	Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia, 2019, 33, 299-312.	7.2	625
3	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discovery, 2019, 9, 370-383.	9.4	380
4	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood, 2013, 121, 4655-4662.	1.4	355
5	Clinical experience with the BCL-2 inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. American Journal of Hematology, 2018, 93, 401-407.	4.1	336
6	Acute myeloid leukemia: current progress and future directions. Blood Cancer Journal, 2021, 11, 41.	6.2	313
7	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology and Oncology, 2019, 12, 1.	17.0	257
8	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncology, The, 2015, 16, 1099-1110.	10.7	249
9	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncology, The, 2015, 16, 1547-1555.	10.7	245
10	The distribution of T cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer, 2019, 125, 1470-1481.	4.1	229
11	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematology, the, 2015, 2, e186-e193.	4.6	227
12	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	1.4	214
13	Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discovery, 2020, 10, 506-525.	9.4	212
14	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematology, the, 2020, 7, e724-e736.	4.6	201
15	TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016, 122, 3484-3491.	4.1	200
16	Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 240-248.	10.7	192
17	Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 2015, 100, 653-661.	3.5	191
18	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematology, the, 2018, 5, e618-e627.	4.6	190

#	ARTICLE	IF	CITATIONS
19	Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. <i>Blood</i> , 2017, 130, 1125-1131.	1.4	180
20	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	1.6	173
21	Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia</i> , 2018, 32, 1094-1105.	7.2	164
22	The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results. <i>Blood</i> , 2019, 134, 569-569.	1.4	161
23	Hyper-FCVAD plus ponatinib versus hyper-FCVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2016, 122, 3650-3656.	4.1	156
24	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	1.6	156
25	A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. <i>Cancer</i> , 2017, 123, 3229-3240.	4.1	155
26	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2015, 90, 276-281.	4.1	139
27	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 897-901.	0.4	127
28	T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. <i>Leukemia</i> , 2021, 35, 1843-1863.	7.2	123
29	Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E202.	4.1	116
30	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. <i>Cancer</i> , 2017, 123, 4391-4402.	4.1	114
31	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015, 125, 3236-3245.	1.4	113
32	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	5.2	106
33	Frontline treatment of acute myeloid leukemia in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 20-34.	4.4	105
34	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 5681-5689.	5.2	105
35	A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. <i>Nature Medicine</i> , 2022, 28, 1212-1223.	30.7	104
36	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e480-e488.	4.6	103

#	ARTICLE	IF	CITATIONS
37	New directions for emerging therapies in acute myeloid leukemia: the next chapter. <i>Blood Cancer Journal</i> , 2020, 10, 107.	6.2	96
38	Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1136-1141.	4.1	95
39	Outcome of patients with low-risk and intermediate-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium. <i>Cancer</i> , 2015, 121, 876-882.	4.1	93
40	Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071982731.	2.5	93
41	The emerging role of immune checkpoint based approaches in AML and MDS. <i>Leukemia and Lymphoma</i> , 2018, 59, 790-802.	1.3	90
42	Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. <i>Cancer</i> , 2016, 122, 2857-2866.	4.1	88
43	Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. <i>Lancet Haematology</i> , 2015, 2, e376-e383.	4.6	86
44	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 482-495.	5.2	86
45	Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. <i>Blood</i> , 2014, 124, 389-389.	1.4	86
46	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. <i>Oncotarget</i> , 2016, 7, 14172-14187.	1.8	86
47	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 25.	6.2	85
48	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e29-e37.	4.6	84
49	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <i>Blood Advances</i> , 2017, 1, 1312-1323.	5.2	83
50	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e552-e561.	4.6	81
51	Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. <i>Cancer</i> , 2021, 127, 3772-3781.	4.1	80
52	Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Cancer</i> , 2018, 124, 2758-2765.	4.1	78
53	Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. <i>Haematologica</i> , 2020, 105, 697-707.	3.5	78
54	HyperCVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	4.1	74

#	ARTICLE	IF	CITATIONS
55	Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. <i>Current Opinion in Hematology</i> , 2018, 25, 136-145.	2.5	73
56	Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 4048-4059.	1.6	73
57	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. <i>Leukemia Research</i> , 2015, 39, 950-956.	0.8	69
58	Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. <i>American Journal of Hematology</i> , 2018, 93, 371-374.	4.1	68
59	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. <i>Lancet Haematology</i> , 2018, 5, e411-e421.	4.6	66
60	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 426-435.	4.1	63
61	Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2019, 125, 2579-2586.	4.1	63
62	CPX-351 (vyxeos) in AML. <i>Leukemia and Lymphoma</i> , 2020, 61, 288-297.	1.3	63
63	Immunotherapy in Acute Myeloid Leukemia: Where We Stand. <i>Frontiers in Oncology</i> , 2021, 11, 656218.	2.8	63
64	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. <i>Blood</i> , 2018, 132, 1664-1674.	1.4	62
65	FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. <i>Blood Cancer Journal</i> , 2021, 11, 104.	6.2	61
66	A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 344-344.	1.4	60
67	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. <i>American Journal of Hematology</i> , 2021, 96, 282-291.	4.1	59
68	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 325-334.	4.1	57
69	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	5.2	56
70	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Oncotarget</i> , 2018, 9, 9714-9727.	1.8	56
71	Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. <i>Blood</i> , 2022, 140, 1753-1763.	1.4	56
72	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2018, 93, 277-285.	4.1	54

#	ARTICLE	IF	CITATIONS
73	Myeloid/lymphoid neoplasms with <i>FGFR1</i> rearrangement. <i>Leukemia and Lymphoma</i> , 2018, 59, 1672-1676.	1.3	53
74	Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. <i>Acta Haematologica</i> , 2020, 143, 567-573.	1.4	53
75	Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. <i>Leukemia Research</i> , 2017, 59, 110-116.	0.8	53
76	Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 763-763.	1.4	53
77	Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S105-S110.	0.4	52
78	Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 803-811.	4.1	51
79	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. <i>American Journal of Hematology</i> , 2020, 95, 612-622.	4.1	51
80	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with <i>NPM1</i> and <i>FLT3</i> internal tandem duplication genotypes. <i>Cancer</i> , 2019, 125, 1091-1100.	4.1	50
81	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II <i>FLT3</i> Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	5.0	50
82	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467.	4.1	49
83	Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 562558.	2.8	49
84	Effective Menin inhibitor-based combinations against AML with <i>MLL</i> rearrangement or <i>NPM1</i> mutation (<i>NPM1c</i>). <i>Blood Cancer Journal</i> , 2022, 12, 5.	6.2	49
85	Detectable <i>FLT3</i> -ITD or <i>RAS</i> mutation at the time of transformation from MDS to AML predicts for very poor outcomes. <i>Leukemia Research</i> , 2015, 39, 1367-1374.	0.8	48
86	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1755-1763.	5.8	48
87	A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 465-465.	1.4	48
88	Efficacy and safety of enasidenib and azacitidine combination in patients with <i>IDH2</i> mutated acute myeloid leukemia and not eligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2022, 12, 10.	6.2	48
89	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≥60 years with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2013, 88, 961-966.	4.1	46
90	Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. <i>Haematologica</i> , 2015, 100, 1058-63.	3.5	46

#	ARTICLE	IF	CITATIONS
91	An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2022, 139, 1098-1110.	1.4	46
92	<i>TP53</i> copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. <i>Blood</i> , 2022, 140, 58-72.	1.4	46
93	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , 2021, 12, 6071.	12.8	44
94	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	4.6	43
95	Poor outcomes associated with +der(22)t(9;22) and <i>9p</i> in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. <i>American Journal of Hematology</i> , 2017, 92, 238-243.	4.1	41
96	Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. <i>American Journal of Hematology</i> , 2017, 92, 7-11.	4.1	41
97	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	1.6	41
98	Mutational landscape of myelodysplastic/myeloproliferative neoplasm "unclassifiable". <i>Blood</i> , 2018, 132, 2100-2103.	1.4	40
99	Outcomes in patients with newly diagnosed <i>TP53</i> -mutated acute myeloid leukemia with or without venetoclax-based therapy. <i>Cancer</i> , 2021, 127, 3541-3551.	4.1	40
100	AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S290.	0.4	40
101	Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2019, 134, 734-734.	1.4	40
102	Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2016, 145, 769-777.	0.7	39
103	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. <i>American Journal of Hematology</i> , 2017, 92, 331-337.	4.1	39
104	Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. <i>Blood</i> , 2020, 135, 449-452.	1.4	39
105	IDH1/IDH2 Inhibition in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 639387.	2.8	39
106	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3755-3766.	4.1	38
107	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. <i>Blood</i> , 2019, 134, 830-830.	1.4	38
108	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. <i>Cancer</i> , 2017, 123, 4430-4439.	4.1	37

#	ARTICLE	IF	CITATIONS
109	Outcome of patients with IDH1/2-mutated post-acute myeloid leukemia in the era of IDH inhibitors. <i>Blood Advances</i> , 2020, 4, 5336-5342.	5.2	37
110	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2489-2492.	7.2	37
111	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. <i>Blood Advances</i> , 2022, 6, 4006-4014.	5.2	37
112	Targeting Immune Checkpoints in Hematologic Malignancies. <i>Pharmacological Reviews</i> , 2016, 68, 1014-1025.	16.0	36
113	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 845-850.	4.1	36
114	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. <i>Blood Advances</i> , 2021, 5, 2173-2183.	5.2	35
115	Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 2900-2900.	1.4	35
116	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. <i>Blood</i> , 2017, 130, 723-723.	1.4	35
117	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Haematologica</i> , 2021, 106, 2121-2130.	3.5	34
118	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2489-2499.	4.1	34
119	A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771.	4.1	34
120	Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 283-283.	1.4	34
121	Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study. <i>Blood</i> , 2019, 134, 3910-3910.	1.4	34
122	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. <i>Blood</i> , 2022, 139, 907-921.	1.4	34
123	The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 504-510.	4.1	33
124	Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. <i>Haematologica</i> , 2018, 103, 1642-1653.	3.5	33
125	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 2193-2205.	4.1	33
126	Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. <i>Blood Advances</i> , 2021, 5, 2156-2164.	5.2	33

#	ARTICLE	IF	CITATIONS
127	Prognostic factors for progression in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 2648-2656.	4.1	33
128	<scp>Treatmentâ€free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 856-864.	4.1	33
129	Hypomethylating agent and venetoclax with FLT3 inhibitor â€œtripletâ€ therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	6.2	33
130	Prognostic significance of baseline <i>FLT3</i>â€TD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	4.1	32
131	Phase II study of azacitidine with pembrolizumab in patients with intermediateâ€1 or higherâ€risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2021, 195, 378-387.	2.5	32
132	Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. <i>Blood Cancer Journal</i> , 2021, 11, 162.	6.2	32
133	Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 73-95.	1.6	31
134	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. <i>Blood</i> , 2021, 138, 1373-1377.	1.4	31
135	Venetoclax combined with <scp>FLAGâ€IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	4.1	31
136	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. <i>Blood</i> , 2019, 134, 229-229.	1.4	30
137	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. <i>Leukemia Research</i> , 2014, 38, 1126-1129.	0.8	29
138	Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. <i>Blood Advances</i> , 2020, 4, 6117-6126.	5.2	29
139	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1288-1295.	4.1	28
140	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with <i>NPM1</i>â€mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1054-1063.	2.5	28
141	Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e115-e118.	0.4	27
142	Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. <i>Lancet Haematology</i> , 2021, 8, e922-e933.	4.6	27
143	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	4.6	26
144	Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. <i>Leukemia Research</i> , 2013, 37, 1440-1444.	0.8	25

#	ARTICLE	IF	CITATIONS
145	Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2019, 109, 545-552.	1.6	25
146	Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. <i>American Journal of Hematology</i> , 2022, 97, 68-78.	4.1	25
147	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	4.1	24
148	Superior efficacy of co-targeting GF11/KDM1A and BRD4 against AML and post-MPN secondary AML cells. <i>Blood Cancer Journal</i> , 2021, 11, 98.	6.2	24
149	Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. <i>Cancer</i> , 2021, 127, 4213-4220.	4.1	24
150	Outcomes of acute lymphoblastic leukemia with <i>KMT2A</i> (<i>MLL</i>) rearrangement: the MD Anderson experience. <i>Blood Advances</i> , 2021, 5, 5415-5419.	5.2	24
151	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. <i>Cancer</i> , 2018, 124, 2534-2540.	4.1	23
152	Prediction for sustained deep molecular response of <i>BCR-ABL1</i> levels in patients with chronic myeloid leukemia in chronic phase. <i>Cancer</i> , 2018, 124, 1160-1168.	4.1	23
153	Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection. <i>Cancer Management and Research</i> , 2019, Volume 11, 8817-8828.	1.9	23
154	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1000-1007.	4.1	23
155	Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study. <i>Blood</i> , 2020, 136, 20-22.	1.4	23
156	Phase 1 study of combinatorial sorafenib, <i>G-CSF</i> , and plerixafor treatment in relapsed/refractory, <i>FLT3-ITD</i> -mutated acute myelogenous leukemia patients. <i>American Journal of Hematology</i> , 2020, 95, 1296-1303.	4.1	22
157	Treatment of Hairy Cell Leukemia During Pregnancy: Are Purine Analogues and Rituximab Viable Therapeutic Options. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 86-89.	0.4	21
158	Targeting CD47/SIRP α in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 67-71.	1.4	21
159	Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML. , 2021, 9, e002968.		21
160	Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. <i>Frontiers in Immunology</i> , 2020, 11, 590494.	4.8	21
161	Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 905-905.	1.4	21
162	Gilteritinib clinical activity in relapsed/refractory <i>FLT3</i> mutated acute myeloid leukemia previously treated with <i>FLT3</i> inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 322-328.	4.1	21

#	ARTICLE	IF	CITATIONS
163	Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. <i>European Journal of Haematology</i> , 2017, 99, 536-543.	2.2	20
164	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2238-2241.	1.3	20
165	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019, 94, 1382-1387.	4.1	20
166	Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. <i>American Journal of Managed Care</i> , 2018, 24, S347-S355.	1.1	20
167	Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis. <i>Lancet Oncology</i> , The, 2017, 18, 1571-1573.	10.7	19
168	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. <i>Cancer</i> , 2020, 126, 4322-4331.	4.1	19
169	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. <i>American Journal of Hematology</i> , 2021, 96, 241-250.	4.1	19
170	Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E154-E157.	4.1	19
171	Impact of frontline treatment approach on outcomes of myeloid blast phase CML. <i>Journal of Hematology and Oncology</i> , 2021, 14, 94.	17.0	19
172	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1733-1739.	1.4	19
173	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 286-286.	1.4	19
174	Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). <i>Blood</i> , 2019, 134, 290-290.	1.4	19
175	Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 97-116.	1.6	18
176	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. <i>Journal of Hematology and Oncology</i> , 2020, 13, 132.	17.0	18
177	Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial. <i>Blood</i> , 2020, 136, 19-20.	1.4	18
178	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. <i>American Journal of Hematology</i> , 2018, 93, 1376-1383.	4.1	17
179	An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E229-E232.	4.1	17
180	Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. <i>Blood Advances</i> , 2021, 5, 3163-3173.	5.2	17

#	ARTICLE	IF	CITATIONS
181	Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. <i>Blood</i> , 2020, 136, 18-20.	1.4	17
182	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. <i>Blood Advances</i> , 2022, 6, 3027-3035.	5.2	17
183	Malignancy-associated haemophagocytic lymphohistiocytosis in adults. <i>Lancet Oncology</i> , The, 2017, 18, 169-171.	10.7	16
184	Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2020, 136, 11-13.	1.4	16
185	Improved survival of patients with myelofibrosis in the last decade: Single-center experience. <i>Cancer</i> , 2022, , .	4.1	16
186	Immune checkpoint inhibitors in acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101247.	1.7	15
187	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. <i>Cancer</i> , 2021, 127, 2641-2647.	4.1	15
188	Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. <i>Blood Advances</i> , 2021, 5, 4569-4574.	5.2	15
189	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. <i>Blood</i> , 2019, 134, 2637-2637.	1.4	15
190	Improved outcomes among newly diagnosed patients with <sc>FMS-like tyrosine kinase 3 internal tandem duplication</sc> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. <i>American Journal of Hematology</i> , 2022, 97, 329-337.	4.1	15
191	Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway. <i>American Journal of Managed Care</i> , 2018, 24, S356-S365.	1.1	15
192	Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. <i>Cancer</i> , 2019, 125, 3219-3224.	4.1	14
193	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818.		14
194	Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≥ 65 yrs) with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1639-1639.	1.4	14
195	Hemophagocytic lymphohistiocytosis in adults: An under recognized entity. <i>BBA Clinical</i> , 2017, 7, 36-40.	4.1	13
196	Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. <i>Frontiers in Oncology</i> , 2020, 10, 588876.	2.8	13
197	Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 914-924.	4.1	13
198	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. <i>Journal of Hematology and Oncology</i> , 2022, 15, 12.	17.0	13

#	ARTICLE	IF	CITATIONS
199	Immunotherapy based approaches in myelofibrosis. <i>Expert Review of Hematology</i> , 2017, 10, 903-914.	2.2	12
200	Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. <i>Blood</i> , 2018, 132, 36-36.	1.4	12
201	Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2640-2640.	1.4	12
202	Prediction of survival with intensive chemotherapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 865-876.	4.1	12
203	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2161-2170.	1.3	12
204	Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL. <i>Blood</i> , 2016, 128, 1316-1317.	1.4	11
205	Phase II study of single-agent nivolumab in patients with myelofibrosis. <i>Annals of Hematology</i> , 2021, 100, 2957-2960.	1.8	11
206	Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 2647-2647.	1.4	11
207	Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2017, 130, 815-815.	1.4	11
208	Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 691-691.	1.4	11
209	The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S3.	0.4	10
210	Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e1-e2.	2.0	10
211	Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e871-e882.	0.4	10
212	Phase 2 study of hyperacMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, 734-739.	4.1	10
213	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. <i>Cancer</i> , 2021, 127, 381-390.	4.1	10
214	Development of TP53 mutations over the course of therapy for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1420-1428.	4.1	10
215	Acute myeloid leukemia: advancing clinical trials and promising therapeutics. <i>Expert Review of Hematology</i> , 2016, 9, 433-445.	2.2	9
216	Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. <i>Blood Advances</i> , 2019, 3, 1533-1539.	5.2	9

#	ARTICLE	IF	CITATIONS
217	Impact of <i>CD33</i> and <i>ABCB1</i> single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. <i>American Journal of Hematology</i> , 2020, 95, E225-E228.	4.1	9
218	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<i>MDS/MPN-RS-T</i>) and myelodysplastic syndrome with ring sideroblasts (<i>MDS-RS</i>). <i>American Journal of Hematology</i> , 2021, 96, E246-E249.	4.1	9
219	Gilteritinib combination therapies in pediatric patients with <i>FLT3</i> -mutated acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 5215-5219.	5.2	9
220	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 645-645.	1.4	9
221	Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2015, 126, 461-461.	1.4	9
222	Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 574-582.	4.1	9
223	Resistance to targeted therapies: delving into <i>FLT3</i> and <i>IDH</i> . <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	9
224	â€”JAKâ€”ingâ€”™ up the treatment of primary myelofibrosis. <i>Current Opinion in Hematology</i> , 2017, 24, 115-124.	2.5	8
225	From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia. <i>Drugs</i> , 2019, 79, 1177-1186.	10.9	8
226	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E50-E53.	4.1	8
227	An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 89-96.	2.3	8
228	Venetoclax, <i>FLT3</i> Inhibitor and Decitabine in <i>FLT3</i> mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. <i>Blood</i> , 2020, 136, 53-55.	1.4	8
229	Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 2736-2745.	4.1	8
230	Sorafenib and novel multikinase inhibitors in AML. <i>Lancet Oncology</i> , The, 2015, 16, 1582-1583.	10.7	7
231	<i>FLT3</i> inhibition in acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2017, 18, 988-989.	10.7	7
232	A bispecific approach to improving CAR T cells in AML. <i>Blood</i> , 2020, 135, 703-704.	1.4	7
233	Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML). , 2016, , .		7
234	A Phase 1b/2 Study of the <i>CD123</i> -Targeting Antibody-Drug Conjugate <i>IMGN632</i> As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with <i>CD123</i> -Positive Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2601-2601.	1.4	7

#	ARTICLE	IF	CITATIONS
235	Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2541-2541.	1.4	7
236	CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 800110.	2.8	7
237	Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 279-280.	1.3	6
238	Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1) Tj ETQq0 0 0 rgBT /Overlock 10 acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2711-2714.	1.3	6
239	Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1665-1673.	4.1	5
240	Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. <i>Cancer</i> , 2021, 127, 1894-1900.	4.1	5
241	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 52.	6.2	5
242	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. <i>Cancer</i> , 2021, 127, 3113-3124.	4.1	5
243	Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML. <i>Blood</i> , 2019, 134, 1428-1428.	1.4	5
244	Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. <i>Leukemia and Lymphoma</i> , 2017, 58, 866-871.	1.3	4
245	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. <i>American Journal of Hematology</i> , 2019, 94, E188-E190.	4.1	4
246	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline <i>RUNX1</i> mutations. <i>American Journal of Hematology</i> , 2020, 95, E313-E315.	4.1	4
247	Clinical value of event-free survival in acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 1690-1699.	5.2	4
248	SOHO State of the Art Updates and Next Questions: Harnessing Apoptosis in AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 133-139.	0.4	4
249	Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 11-12.	1.4	4
250	Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. <i>Blood Cancer Journal</i> , 2022, 12, 23.	6.2	4
251	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. <i>American Journal of Hematology</i> , 2022, 97, 885-894.	4.1	4
252	A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101220.	1.7	3

#	ARTICLE	IF	CITATIONS
253	A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule 1 (CLL1) in patients with acute myeloid leukemia. American Journal of Hematology, 2021, 96, E175-E179.	4.1	3
254	FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. American Journal of Hematology, 2021, 96, E275-E279.	4.1	3
255	Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia. Clinical Cancer Research, 2021, 27, 5739-5741.	7.0	3
256	Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis. Blood, 2020, 136, 30-33.	1.4	3
257	Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood, 2014, 124, 3671-3671.	1.4	3
258	Infectious complications among patients with AML treated with immune checkpoint inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	3
259	Adult cancer-related hemophagocytic lymphohistiocytosis – a challenging diagnosis: a case report. Journal of Medical Case Reports, 2017, 11, 172.	0.8	2
260	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). American Journal of Hematology, 2020, 95, E326-E329.	4.1	2
261	Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. American Journal of Hematology, 2021, 96, E350-E353.	4.1	2
262	Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leukemia and Lymphoma, 2021, , 1-5.	1.3	2
263	Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. Blood, 2019, 134, 2582-2582.	1.4	2
264	Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. Blood, 2016, 128, 3171-3171.	1.4	2
265	Philadelphia–positive dimorphic blasts in mixed–phenotype acute leukemia with TET2 mutation. American Journal of Hematology, 2016, 91, 647-648.	4.1	1
266	An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. Advances in Experimental Medicine and Biology, 2021, 1342, 273-295.	1.6	1
267	Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia. Cancer Journal (Sudbury, Mass), 2022, 28, 43-50.	2.0	1
268	Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy. Blood Advances, 2022, 6, 5546-5549.	5.2	1
269	Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. Blood Advances, 2023, 7, 828-831.	5.2	1
270	AML: The future is now or was it yesterday?. Best Practice and Research in Clinical Haematology, 2019, 32, 115.	1.7	0

#	ARTICLE	IF	CITATIONS
271	Taking aim at IDH in fitter patients with AML. Blood, 2021, 137, 1706-1707.	1.4	0
272	A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules. Statistics in Medicine, 2021, 40, 4629-4639.	1.6	0
273	Hemophagocytic Lymphohistiocytosis in the Cancer Patient. , 2020, , 1155-1161.		0
274	A nonstick marrow may help to fry leukemia. Blood, 2022, 139, 1119-1121.	1.4	0